Earnings

Actinium Pharmaceuticals To Present Data And Preclinical Results For ANTM-400 At The Congress Of The European Association Of Nuclear Medicine, October 17–21

Oct 19, 2026 · 07:37 AM ET· updated 1h ago

First-in-human Phase 1 presentation to feature ATNM-400 clinical data in metastatic castration-resistant prostate cancer, advancing a differentiated approach beyond PSMAPreclinical presentation to feature ATNM-400

Why It Matters

Actinium will show early test results for a new cancer medicine at a big conference. This shows the company is moving forward with its treatment development work.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ATNM1.13

+0.00 (+0.00%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.